Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy-Reference-Cited by-同舟云学术

Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy

Published:2007-06 Issue:3 Volume:56 Page:383-389
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Sunaga Noriaki,Tomizawa Yoshio,Yanagitani Noriko,Iijima Hironobu,Kaira Kyoichi,Shimizu Kimihiro,Tanaka Shigebumi,Suga Tatsuo,Hisada Takeshi,Ishizuka Tamotsu,Saito Ryusei,Dobashi Kunio,Mori Masatomo

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference39 articles.

1. Targeting HER1/EGFR: a molecular approach to cancer therapy;Arteaga;Semin Oncol,2003

2. Molecular genetics of lung cancer;Sekido;Annu Rev Med,2003

3. Epidermal growth factor receptor expression, signal pathway, and inhibitors in non-small cell lung cancer;Bunn;Semin Oncol,2002

4. EGFR and cancer prognosis;Nicholson;Eur J Cancer,2001

5. FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets;Cohen;Oncologist,2003

Cited by 116 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Gefitinib-Induced Severe Dermatological Adverse Reactions: A Case Report and Pharmacogenetic Profile;Pharmaceuticals;2024-08-07

2. QT-Interval Prolongation, Torsades de Pointes, and Heart Failure With EGFR Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: Systematic Review;Clinical Lung Cancer;2024-06

3. The Treatment of a Novel Epidermal Growth Factor Receptor (EGFR)-GRB2 Genetic Mutation Using Osimertinib in Metastatic Non-Small Cell Lung Cancer;Cureus;2023-04-24

4. Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management;Nature Reviews Clinical Oncology;2022-05-09

5. Reporting of Incidence and Outcome of Bone Metastases in Clinical Trials Enrolling Patients with Epidermal Growth Factor Receptor Mutated Lung Adenocarcinoma—A Systematic Review;Cancers;2021-06-23